List of Resources

Cancer Risk and Genetics	2
Cancer Screening	
Screening and Prevention Options	2
Guidelines by Gene	2
Reconstruction & Going Flat	2
Treatment	
Treatment Options	3
Treatment Research	3
Support	3
Public Policy	
FORCE Public Policy	3
Partner Public Policy	3
More FORCE Partners	4
Additional Resources	
Glossary of Terms	4
Feedback Survey	4
Webinar Slides	4

Hereditary Breast Cancer Resources

Cancer Risk and Genetics

- How to Get Genetic Testing
- Sharing Health Information with Relatives
- Genetic Testing for People Diagnosed with Breast Cancer
- Find a Genetic Counselor
- Hereditary Breast Cancer Risk



Breast Cancer Screening and Prevention

- Breast Cancer Screening Options
- Medications to Reduce Breast Cancer Risk
- Surgery to Reduce Breast Cancer Risk



- Cancer screening guidelines by gene
    - ATM
    - BARD1
    - BRCA1
    - BRCA2
    - CDH1
    - CHEK2
    - NF1
    - PALB2
    - PTEN
    - RAD51C
    - RAD51D
    - STK11
    - TP53



Breast Reconstruction or Going Flat Resources

- Reconstruction or Going Flat
- Post-Mastectomy Photo Gallery
- The Complete Guide to Breast Reconstruction



Breast Cancer Treatment

- Hereditary Breast Cancer Treatment Information
- Breast Cancer Stages and Subtypes
- Treatment Options for Breast Cancer
- Biomarker Testing
- Genetic Testing
- Targeted and Immunotherapies



Treatment Research

- Breast cancer treatment research listings on FORCE
- Looking at Tumor DNA Before Chemotherapy to Predict Cancer Recurrence in People with High-Risk, Early-Stage Breast Cancer
- Studying a New PARP Inhibitor and Hormonal Therapy to Treat HER2-negative, HR-positive Metastatic Breast Cancer with a BRCA1, BRCA2, or PALB2 Mutation (EvoPAR BR01)
- Treating Advanced Cancers with BRCA or Other Related Gene Mutations Using Targeted Therapy MOMA-313 Alone or In Combination with the PARP Inhibitor Olaparib
- Study of a New Investigational Inhibitor to Treat People with Advanced Solid Tumors
- Treating HER2-negative, Metastatic Breast Cancer with a BRCA or PALB2 Mutation Using a New Drug Combined with Olaparib
- Olaparib with Cediranib or Ceralasertib for People with Advanced or Metastatic Breast Cancer and with a BRCA1 or BRCA2 Mutation



Hereditary Breast Cancer Support

- FORCE support programs
    - Peer Navigation Program
    - Support Meetings
    - Message Boards
    - Private FaceBook Group



Public Policy

- FORCE Policy Priorities
    - FORCE Federal Policy Initiatives
    - FORCE State Policy Initiatives
    - Get Involved



- Susan G. Komen Public Policy Priorities
- American Cancer Society: Cancer Action Network
- National Coalition for Cancer Survivorship Public Policy

FORCE Partners

- Breast Cancer Resource Center
- Cancer Support Community
- HIS Breast Cancer Awareness
- Living Beyond Breast Cancer
- MBCure
- Metastatic Breast Cancer Alliance
- SHARE
- Susan G. Komen
- Tigerlily Foundation
- TOUCH: The Black Breast Cancer Alliance
- Triage Cancer
- Young Survival Coalition

Additional Resources

Glossary of Terms

Feedback Survey

Webinar Slides